PubMed · 16048169
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
David P Tarantino. Using value innovation to create competitive advantage (part I).. https://pubmed.ncbi.nlm.nih.gov/16048169/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
Obesity has been described as an abnormality arising from the evolution of man, who becomes fat during the time of perpetual plenty. From the perspective of "Darwinian Medicine," if famine is avoided, obesity will prevail. Problems regarding obesity arise within many disciplines, including socioeconomic environments, the educational system, science, law, and government. This article will discuss various ethical aspects of several disciplines regarding obesity, with a focus on scientific inquiry. We will discuss this within the categories: (1) chronic kidney disease predialysis, (2) dialysis, and (3) renal transplantation. This article aims to help nephrologists and their patients navigate through the ethical aspects of obesity and chronic kidney disease.
(1) Intragastric balloons are a temporary non-surgical obesity treatment that induces short-term weight loss by partially filling the stomach to achieve satiety and reduce food intake. (2) Moderate weight loss may be achieved if patients adhere to a weight-reduction program. Weight gain often recurs when the balloon is removed after six months. (3) Abdominal pain, nausea, and vomiting are common, particularly in the first week after balloon implantation. (4) More data on benefits, harm, and cost effectiveness are required before the intragastric balloon can be compared with other short-term weight loss interventions, including low-calorie diets.